论文部分内容阅读
目的:探讨血管内皮生长因子(VEGF)、基质金属蛋白酶-9(MMP-9)及环氧化酶-2(COX-2)在甲状腺癌组织中的表达情况及其与临床特征的关系。方法:SP法检测100例甲状腺癌及20例癌旁正常甲状腺组织中VEGF、MMP-9及COX-2的表达。观察其与患者临床病理及预后的关系。结果:甲状腺癌组织中,VEGF、MMP-9和COX-2的阳性率分别为70%(70/100)、68%(68/100)和63%(63/100),显著高于癌旁组织,P<0.01;三者阳性率高低与甲状腺癌的临床分期和淋巴结转移密切相关,P<0.01;VEGF、COX-2的阳性表达与甲状腺癌的组织类型有关,P<0.05。结论:甲状腺癌组织VEGF、MMP-9及COX-2的表达与临床分期及淋巴结转移有关,可作为甲状腺癌患者的预后指标。
Objective: To investigate the expression of vascular endothelial growth factor (VEGF), matrix metalloproteinase-9 (MMP-9) and cyclooxygenase-2 (COX-2) in thyroid cancer and their relationship with clinical features. Methods: SP method was used to detect the expression of VEGF, MMP-9 and COX-2 in 100 cases of thyroid cancer and 20 cases of normal thyroid tissue adjacent to cancer. Observe its relationship with clinical pathology and prognosis of patients. Results: The positive rates of VEGF, MMP-9, and COX-2 in thyroid cancer tissues were 70% (70/100), 68% (68/100), and 63% (63/100), respectively, which were significantly higher than those adjacent to cancer. Tissue, P<0.01; The positive rates of the three were closely related to the clinical stage and lymph node metastasis of thyroid cancer, P<0.01; The positive expression of VEGF and COX-2 was related to the tissue type of thyroid cancer, P<0.05. Conclusion: The expression of VEGF, MMP-9 and COX-2 in thyroid cancer is related to clinical stage and lymph node metastasis. It can be used as a prognostic indicator for thyroid cancer.